Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp WH, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich HT, Mueller RP, Fuchs M, Borchmann P, Schicha H, Diehl V, Engert A.
Kobe C, et al. Among authors: borchmann p.
Blood. 2008 Nov 15;112(10):3989-94. doi: 10.1182/blood-2008-06-155820. Epub 2008 Aug 29.
Blood. 2008.
PMID: 18757777
Free PMC article.
Clinical Trial.